Treatment of chronic prostatitis in Chinese men

Abstract

The aim of this study is to assess the status of treatment of chronic prostatitis (CP) in Chinese men. A population-based cross-sectional survey was performed, in which 15 000 men aged between 15 and 60 years were randomly selected to receive a questionnaire designed to assess National Institutes of Health Chronic Prostatitis Symptoms Index (NIH-CPSI) status, therapeutic efficacy and 28 other items. A total of 12 743 men (84.95%) completed the questionnaire, of whom 1 071 (8.4%) were identified as having prostatitis-like symptoms and 517 (4.5%) were diagnosed with CP according to NIH-CPSI criteria and prostatitis-like symptomatology. Of the CP patients, 372 (65%) underwent long-term routine treatment 12 times per year. Additionally, 217 (72.8%) patients received antibiotic therapy and 215 (79.3%) men showed therapeutic effects. The treatment cost USD 1 151 (8 059 yuan) per person per year on average. Most CP patients received routine treatment, in most cases with antibiotics. Treatment was costly and most CP patients were not satisfied with its effectiveness. Antibacterial treatment might have been effective primarily in patients with bacterial disease.

Validation and Comparison of EuroQol and Short Form 6D in Chronic Prostatitis Patients

“…Chronic prostatitis (CP) is a common condition affecting 2–10% of men around the world [7,8] and 4.5% in China [9], and causes quality of life impairment of its sufferers [10,11]. Since CP is primarily a disease of uncertain etiology with no current “gold standard” for its treatment, the primary goal of CP management is to achieve optimal symptom control and ultimately to improve the patients' HRQoL.…”

“…Nonparametric Mann–Whitney U tests were performed to identify statistically significant effects of the dichotomous variables on utility scores, while Kruskal–Wallis H tests for polytomous variables. The levels of CP severity were defined as mild, moderate, and severe if NIH‐CPSI scores ranged from 0 to 14, 15 to 30, and 31 to 43, respectively [23,9]. EQ‐VAS was adopted as an indicator for self‐reported health status, and we classified the EQ‐VAS scores into four groups, namely <65 (bad), 65 to 79 (fair), 80 to 89 (good), and 90 to 100 (excellent) [24].…”

Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis

“…hronic bacterial prostatitis (CBP) is a troublesome disease, showing an overall clinical and microbiological response rate to fluoroquinolones, the antibiotics of choice, of only 60% (1)(2)(3)(4). In CBP caused by Escherichia coli, the reported resistance rates are 11% to ciprofloxacin and 20% to norfloxacin (5).…”

Health-related quality of life in Chinese patients with chronic prostatitis/chronic pelvic pain syndrome

“…NIH-CPSI has been accepted by the International Prostatitis Collaborative Network as the standard and valid instrument for evaluating men with chronic prostatitis symptoms [20,22]. The Chinese NIH-CPSI has been validated and used wildly in scientific research and clinical observation [1,23,24].…”